Market Access Preparing for the pharma fraud enforcement surge Here is what robust, risk-based compliance looks like in 2026.
News NICE finally backs Enhertu for HER2-low breast cancer Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
